169205-99-6

Usage

Uses

Used in Pharmaceutical Research:
Oxazolo[5,4-b]pyridine-2(1H)-thione is utilized as a key building block for the synthesis of bioactive molecules, contributing to the development of new pharmaceutical agents. Its unique structure allows for the creation of diverse compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
Oxazolo[5,4-b]pyridine-2(1H)-thione serves as an interesting target for medicinal chemists, who explore its properties and potential interactions with biological targets. Its exploration can lead to advancements in drug discovery and the design of novel therapeutic agents.
Used in Drug Development:
Oxazolo[5,4-b]pyridine-2(1H)-thione is employed in the process of drug development, where its biological activity and structural features are harnessed to create new pharmaceuticals with improved efficacy and safety profiles.
Used in Materials Science:
Due to its unique structural features and reactivity, Oxazolo[5,4-b]pyridine-2(1H)-thione may have applications in materials science, potentially contributing to the development of new materials with specific properties for various uses.
Used in Organic Synthesis:
Oxazolo[5,4-b]pyridine-2(1H)-thione's reactivity and structural characteristics make it a valuable component in organic synthesis, where it can be used to create a range of organic compounds for different applications, including but not limited to pharmaceuticals, agrochemicals, and specialty chemicals.

Upstream product

• 33630-99-8 2-hydroxy-3-aminopyridine 
• 463-71-8 thiophosgene 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 6332-56-5 2-hydroxy-3-nitropyridine 

Downstream Products

• 213684-61-8 N-(2,6-diisopropylphenyl)-6-(oxazolo[5,4-b]pyridin-2-ylthio)hexanamide 
• 159870-95-8 2-chloro-[1,3]oxazolo[5,4-b]pyridine 

Relevant academic research and scientific papers

HMOX1 inducers

The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS

The present invention relates to a7 nicotinic receptor agonists of formula (la) or (lb) as described herein and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal an a7 nicotinic receptor agonist of formula (la) or (lb). It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant a7nicotinic receptor agonist of formula (la) or (lb).

Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives

This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Non-imidazole histamine H3 ligands. Part III. New 4-n-propylpiperazines as non-imidazole histamine H3-antagonists

In search for a new lead of non-imidazole histamine H3-receptor antagonists, a series of 1[(2-thiazolopyridine)-4-n-propyl]piperazines, the analogous 1-[(2-oxazolopyridine)-4-npropyl]piperazines, 1-[(2-benzothiazole)-4- n-propyl]piperazine and 1-[(2-benzooxazole)4-n-propyl]piperazine were prepared and in vitro tested as H3-receptor antagonists (the electrically evoked contraction of the guinea-pig jejunum). It appeared that by comparison of homologous pairs the thiazolo derivatives have slightly higher activity than their oxazolo analogues. The most potent compound of these series is the 1-(2-thiazolo[4,5-c]pyridine)-4-n-propylpiperazine (3c) with pA2 = 7.25 (its oxazole analogue (4g) showed pA2 = 6.9). The structure-activity relationships for compounds with various positions of the nitrogen in the benzene ring for the thiazoles compared with oxazoles are discussed.